FDA Finds Gaps at Another Indian Drugmaker

NEW DELHI: The US Food and Drug Administration (FDA) has found nine deviations in Indian drug maker Cipla's manufacturing process during a recent inspection of the company's Bangalore plant. The Mumbai-based company, however, said the deviations are minor ones relating to manufacturing practices.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.